Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Non Operating Investment Income (2019 - 2023)

Benitec Biopharma has reported Non Operating Investment Income over the past 5 years, most recently at -$1000.0 for Q4 2023.

  • Quarterly results put Non Operating Investment Income at -$1000.0 for Q4 2023, up 66.67% from a year ago — trailing twelve months through Dec 2024 was -$1000.0 (up 75.0% YoY), and the annual figure for FY2024 was -$1000.0, up 66.67%.
  • Non Operating Investment Income reached -$1000.0 in Q4 2023 per BNTC's latest filing, down from $1000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $19000.0 in Q2 2021 and bottomed at -$23000.0 in Q4 2021.
  • Median Non Operating Investment Income over the past 5 years was -$1000.0 (2019), compared with a mean of $71.43.
  • The largest annual shift saw Non Operating Investment Income plummeted 2200.0% in 2021 before it surged 200.0% in 2023.
  • Over 5 years, Non Operating Investment Income stood at -$1000.0 in 2019, then changed by 0.0% to -$1000.0 in 2020, then tumbled by 2200.0% to -$23000.0 in 2021, then skyrocketed by 86.96% to -$3000.0 in 2022, then skyrocketed by 66.67% to -$1000.0 in 2023.
  • Business Quant data shows Non Operating Investment Income for BNTC at -$1000.0 in Q4 2023, $1000.0 in Q2 2023, and -$4000.0 in Q1 2023.